← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #988 OF 1,000 MOST-CITED

Periodic equipment inspection lack of or inadequate procedu

FDA cited this observation 13 times across 13 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices13
BY FISCAL YEAR
FY20252
FY20243
FY20231
FY20221
FY20212
FY20191
FY20183

How FDA worded it — real examples

Procedures for conducting periodic inspections to ensure adherence to equipment maintenance schedules have not been established.

Immuno Diagnostic Center, Inc · Dallas, Texas · Devices · 2025-02-12

Procedures for conducting periodic inspections to ensure adherence to equipment maintenance schedules have not been adequately established.

WEIL INDUSTRIES · Duttlenheim · Devices · 2024-11-07

Procedures for conducting periodic inspections to ensure adherence to equipment maintenance schedules have not been adequately established.

Kawasumi Laboratories (Thailand) Co. Ltd. · Chok Chai · Devices · 2024-07-25

Procedures for conducting periodic inspections to ensure adherence to equipment maintenance schedules have not been established.

CLARITY DESIGN, INC. · Poway, California · Devices · 2024-07-10

Procedures for conducting periodic inspections to ensure adherence to equipment maintenance schedules have not been established.

STERITECH, INC. · Salinas, Puerto Rico · Devices · 2023-12-08

Procedures for conducting periodic inspections to ensure adherence to equipment maintenance schedules have not been adequately established.

ReNovo, Inc. · Bend, Oregon · Devices · 2023-05-18

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Medical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →